SECTION MENU

Mayo Clinic Leads on Long-Term COVID-19 Biorepository

September 29, 2021

Mayo Clinic Leads on Long-Term COVID-19 Biorepository

Mayo Clinic research is dedicated to finding solutions for patients who were infected with COVID-19 and the many affected by the long-term symptoms of COVID-19---what the National Institutes of Health (NIH) refers to as “long COVID” or post-acute sequelae. As part of NIH’s REsearching COVID to Enhance Recovery (RECOVER) Initiative, the NIH awarded $40 million to Mayo Clinic to develop a comprehensive biorepository as the source of clinical samples for long COVID research studies.

A biorepository is a central resource of biospecimen collections to facilitate personalized medicine research. The initiative is a national effort to bring together scientists, clinicians, patients and caregivers to take on the long-term effects of COVID-19. Mayo Clinic and its biorepository core joins New York University and its clinical science core, and Massachusetts General Hospital and its data resource core, as the three initiative cores that will provide the study’s infrastructure and organizational framework. Together, these cores will build and support the initiative, as well as its participant pool and a team of investigators. In addition, Mayo Clinic has received an award for the Post-Acute Sequelae of SARS-CoV-2 Clinic Studies Recovery Network: Clinical Studies Component for Autopsy-Based Studies, also known as PASCnet. This initiative will be led by R. Ross Reichard, M.D., a Mayo Clinic anatomical pathologist, and Mayo Clinic’s COVID-19 Task Force. The Center for Clinical and Translational Science will oversee the research efforts. This work will be in addition to the ongoing clinical and research programs.
   —Visit https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-leads-biorepository-core-for-new-nationwide
-research-on-long-term-symptoms-of-covid-19/
to read more.